Critical Illness Immunological Reprogramming and Control Point Learning Engine (CIRCLE) Innovative Solutions Opening (ISO)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Advanced Research Projects Agency for Health (ARPA-H) has issued an Innovative Solutions Opening (ISO) for the Critical Illness Immunological Reprogramming and Control Point Learning Engine (CIRCLE) program. This solicitation seeks proposals to develop solutions that improve intensive care unit (ICU) health outcomes by assessing, predicting, and treating immuno-inflammatory dysregulation. Multiple Other Transaction (OT) Agreements are anticipated. Full Proposals are due Thursday, May 28, 2026, at 1 PM ET.
Program Overview & Objectives
The CIRCLE program aims to create a Control Point Validation Engine to reduce ICU stay time and associated costs, ultimately improving patient outcomes. The goal is to achieve personalized immunotherapy and potentially reduce average ICU stays by 25% through real-time assessment, prediction, and modulation of immune responses before organ failure occurs.
Technical Areas & Acceleration Platforms
The program is structured around three Technical Areas (TAs) and three Acceleration Platforms (APs):
- TA1: Measure - Dynamic Immune Descriptor: Develop real-time, tissue-specific immuno-inflammation biomarker sensors and diagnostics.
- TA2: Model - Digital Twin Generator: Create personalized computational models (digital twins) to predict critical illness trajectories and identify control points.
- TA3: Modulate - Rational Immune Reprogrammer: Develop and test interventions to modulate the immune response to control critical illness.
- Acceleration Platforms (APs): Provide independent verification, validation, data analysis, FDA-compliant modeling platforms, and clinical trial support.
Contract Details
This is a 5-year, 3-phase program. Awards will be made as Other Transaction (OT) Agreements, with multiple awards anticipated.
- Eligibility: Universities, non-profit organizations, small businesses, and other than small businesses are eligible. FFRDCs and U.S. Government entities cannot participate as prime or sub-performers. Non-U.S. entities may participate if compliant with regulations.
- Set-Aside: None specified; this is an open competition.
- Product Service Code: AN13 (Health R&D Services; Health Care Services; Experimental Development).
Submission Requirements & Evaluation
Proposers must submit a Solution Summary prior to a Full Proposal. Proposals must include a commercialization strategy narrative, and open-source technologies are encouraged. Evaluation criteria include Overall Scientific and Technical Merit, Proposer's Capabilities/Related Experience, Price/Value Analysis, and Relevance to the ARPA-H Mission.
Key Dates
- Proposer's Day: Wednesday, March 11, 2026
- Solution Summaries Due: Monday, March 30, 2026, 1 PM ET
- Questions Due: Friday, May 22, 2026, 1 PM ET
- Full Proposals Due: Thursday, May 28, 2026, 1 PM ET
Amendments & Important Attachments
Amendment 1 confirmed the proposal submission date and replaced "Office of Commercialization" with "ARPA-H." Amendment 2 provided clarifications, updated terminology (e.g., "Program Leads" to "Project Leads"), and added an FAQ portal link. Proposers must utilize mandatory templates for the Solution Summary (Att A), Technical & Management Volume (Att B), Task Description Document (Att C), Price/Cost Proposal Workbook (Att D), and Administrative and National Policy (Att F). A Model OT Agreement (Att E) is also provided for review.